OBJECTIVE Parkinson's disease (PD) patients are usually treated with L-dopa and/or dopaminergic agonists, which act by binding five types of dopaminergic receptors (DRD1-DRD5). Peripheral immune cells are known to express dopamine receptors on their membrane surface, and therefore they could be directly affected by the treatment. Regulatory cells are the main modulators of inflammation, but it is not clear whether dopaminergic treatment could affect their functions. While only regulatory T cells (Tregs) have been proved to express dopamine receptors, it is not known whether other regulatory cells such as CD8regs, regulatory B cells (Bregs), tolerogenic dendritic cells, and intermediate monocytes also express them. METHODS The expression of dopamine receptors in Tregs, CD8regs, Bregs, tolerogenic dendritic cells, and intermediate monocytes was herein evaluated. cDNA from 11 PD patients and 9 control subjects was obtained and analyzed. RESULTS All regulatory cell populations expressed the genes coding for dopamine receptors, and this expression was further corroborated by flow cytometry. These findings may allow us to propose regulatory populations as possible targets for PD treatment. CONCLUSIONS This study opens new paths to deepen our understanding on the effect of PD treatment on the cells of the regulatory immune response.

中文翻译：

---

多巴胺受体在免疫调节细胞中的表达。

目的帕金森氏病（PD）患者通常接受L-多巴和/或多巴胺能激动剂治疗，这些激动剂通过结合五种类型的多巴胺能受体（DRD1-DRD5）发挥作用。已知外周免疫细胞在其膜表面表达多巴胺受体，因此它们可能直接受到治疗的影响。调节细胞是炎症的主要调节剂，但尚不清楚多巴胺能治疗是否会影响其功能。虽然仅调节性T细胞（Tregs）已被证明能表达多巴胺受体，但尚不清楚其他调节性细胞，例如CD8regs，调节性B细胞（Bregs），致耐受性树突状细胞和中间单核细胞是否也表达它们。方法多巴胺受体在Tregs，CD8regs，Bregs，致耐受性树突状细胞中的表达，并且在此评估了中间单核细胞。获得并分析了11名PD患者和9名对照受试者的cDNA。结果所有调节细胞群均表达编码多巴胺受体的基因，流式细胞术进一步证实了这一表达。这些发现可能使我们可以提出规范人群作为PD治疗的可能靶标。结论这项研究开辟了新的途径，以加深我们对PD治疗对调节性免疫应答细胞的影响的理解。这些发现可能使我们可以提出规范人群作为PD治疗的可能靶标。结论这项研究开辟了新的途径，以加深我们对PD治疗对调节性免疫应答细胞的影响的理解。这些发现可能使我们可以提出规范人群作为PD治疗的可能靶标。结论这项研究开辟了新的途径，以加深我们对PD治疗对调节性免疫应答细胞的影响的理解。